<DOC>
	<DOCNO>NCT02542852</DOCNO>
	<brief_summary>Research ipotesis ass efficacy safety nucleos ( ) ide spar regimen atazanavir/ritonavir 300 mg /100 mg QD + Dolutegravir 50 mg QD management virological failure HIV-1 infect patient . The Primary Objective explore 24-week efficacy nucleos ( ) ide spar regimen atazanavir 300 mg QD/ ritonavir 100 mg QD + Dolutegravir 50 mg QD management virologic failure HIV-1 infect , integrase inhibitor-naïve subject .</brief_summary>
	<brief_title>A Study Nucleoside Sparing Regimen HIV-1 Infected Patients With Detectable Viremia</brief_title>
	<detailed_description>Study design ; • 24-week prospective , single-arm , monocentric , open label , pilot study Participants see screen , baseline , day 8 week 4 , 8 , 12 , 16 , 24 . At visit follow evaluation perform : - clinical assessment . - routine laboratory test ( hematological test clinical chemistry ) include hemochromocytometric examination leukocytic formula , creatinine , creatine kinase , transaminase , phosphorus , calcium , alkaline phosphatase , total direct bilirubin , gammaGT , uric acid , lactate dehydrogenase , urine analysis , glucose , lipid profile , HIV-RNA CD4 cell count . Additional blood sample collect visit storage determination . During follow-up , different timepoints , patient additionally undergo : - HbA1c fast insulin level HOMA-IR determination ( baseline , week 12 , week 24 ) - Adherence assessment ( questionnaire and/or pill count ) week 4 , 12 24 . - ECG ( baseline week 24 ) Protocol virologic failure define - &lt; 1 log10 decrease plasma HIV-1 RNA week 12 , subsequent confirmation , unless plasma HIV-RNA &lt; 200 copies/ml OR - confirm rebound plasma HIV-RNA level ≥ 50 copies/ml prior confirm suppression &lt; 50 copies/ml OR confirm plasma increase HIV-1 RNA level &gt; 1log10 copies/ml nadir value nadir ≥ 50 copies/ml OR - plasma HIV-1 RNA level ≥ 50 copies/ml week 24 Subjects meet protocol-defined virologic failure follow-up discontinue study . Patients suppress HIV-1 RNA &lt; 50 cp/ml week 24 viral blip ≥ 50 copies/ml week 24 undergo plasma HIV-1 RNA re-test confirm virologic failure . At virologic failure subject perform genotypic phenotypic test plasma determination ATV DTG Cthrough . No change study treatment allow exception ritonavir ( RTV ) discontinuation patient hyperbilirubinemia and/or gastrointestinal adverse event judge RTV-related Investigator . In case , subject remain study use regimen ATV 400mg QD + DTG 50mg QD . The discontinuation RTV consider treatment failure . In subject plasma HIV-RNA &lt; 50 copies/ml week 24 , study treatment successively provide Italian National Health system .</detailed_description>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Subjects age 18 year Willing able provide inform consent Failing stable ( least 3 month ) antiretroviral therapy ( HIVRNA 200 copies/ml ) Any CD4 cell count Virus susceptible atazanavir , define genotypic mutation score inferior 15 accord HIV drug resistance database ( Stanford University ) No previous document virologic failure atazanavircontaining regimen No previous exposure integrase inhibitor Absolute neutrophil count ( ANC ) 500/mm3 Haemoglobin 8.0 g/dL Platelet count 60,000/mm3 eGFR &gt; 60 ml/min use CKDEPI equation Active AIDSdefining condition Screening Serious illness require systemic treatment and/or hospitalization Current use immunomodulant immunosuppressive drug Requirement concomitant medication prohibit study drug ( protocol section 3.6 ) History presence hypersensitivity active substance excipients Alanine aminotransferase ( ALT ) 5 time upper limit normal ( ULN ) , OR ALT 3xULN bilirubin 1.5xULN ( 35 percent direct bilirubin ) Subjects positive Hepatitis B screening ( HBsAg positive ) Subjects anticipate need Hepatitis C virus ( HCV ) therapy study Presence moderate severe hepatic impairment ( defined Class B C Child Pugh Classification ) presence unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminemia , esophageal gastric varix , persistent jaundice ) know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Pregnancy pregnancy wish ; breastfeed Moreover , clinical condition report absolute contraindication summary product characteristic study drug , consider exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV-1</keyword>
</DOC>